Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 1:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 18,752 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Phase I Clear all

Conditions: Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: ixabepilone; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 3
States / cities: San Antonio, Texas

Conditions: Childhood Chronic Myelogenous Leukemia, Childhood Desmoplastic Small Round Cell Tumor, Disseminated Neuroblastoma, Metastatic Childhood Soft Tissue Sarcoma, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Osteosarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma
Interventions: tanespimycin, pharmacological study, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: New York, New York

Conditions: NY-ESO-1-expressing Tumors
Interventions: Vaccine only, Vaccine + cyclophosphamide; Biological
Lead sponsor: Hassane M. Zarour, MD; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Advanced PD-L1 Positive Malignancies
Interventions: 89Zr˗DFO˗REGN3504; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: Doxorubicin Hydrochloride, Estramustine phosphate sodium, Etoposide, Ketoconazole, Paclitaxel, Vinblastine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Head and Neck Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, Melanoma
Interventions: BDC-3042, Cemiplimab; Drug
Lead sponsor: Bolt Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 6
States / cities: Palo Alto, California • Boston, Massachusetts • Austin, Texas + 3 more

Conditions: Lung Cancer
Interventions: radiofrequency ablation, radiation therapy; Procedure · Radiation
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 120 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Colorectal Cancer, Colon Cancer, Rectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Breast Cancer, Breast Neoplasms
Interventions: hMN14 (labetuzumab); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Breast Carcinoma, Colorectal Adenocarcinoma, Bladder Carcinoma
Interventions: Recombinant human IL-7-hyFc (NT-I7), Vaccine sequence 1, Vaccine sequence 2; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 60 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pancreatic Cancer
Interventions: Capecitabine, Docetaxel, Gemcitabine; Drug
Lead sponsor: Tony Bekaii-Saab; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Columbus, Ohio

Conditions: Healthy Subjects
Interventions: AMG 510; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: bortezomib, topotecan hydrochloride, immunohistochemistry staining method, pharmacological study; Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 2
States / cities: Duarte, California • Pasadena, California

Conditions: Nipah Virus Infection
Interventions: mRNA -1215; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatic Impairment
Interventions: Telotristat Ethyl; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Conditions: Acquired Immunodeficiency Syndrome, HIV Infection
Interventions: PCLUS 3-18 MN, PCLUS 6.1 MN; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type 2 Diabetes Mellitus
Interventions: cotadutide multidose pen injection; Combination Product
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Breast Cancer, Cardiac Toxicity
Interventions: trastuzumab, cyclophosphamide, doxorubicin hydrochloride, lapatinib ditosylate, paclitaxel, gene expression analysis, reverse transcriptase-polymerase chain reaction, fluorophotometry, laboratory biomarker analysis, mass spectrometry, adjuvant therapy, quality-of-life assessment; Biological · Drug · Genetic + 2 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Advanced Malignant Solid Neoplasm
Interventions: EphA2-targeting DOPC-encapsulated siRNA, Laboratory Biomarker Analysis, Pharmacological Study; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: HEC585; Drug
Lead sponsor: Sunshine Lake Pharma Co., Ltd.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 136 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Adolescent Problem Behavior at School, Risk Behavior, Truancy; Socialized
Interventions: XY-Zone; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 13 Years to 20 Years · Male only
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Austin, Texas

Conditions: End Stage Renal Disease on Dialysis, Adult
Interventions: Intravenous fosmanogepix; Drug
Lead sponsor: Basilea Pharmaceutica; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Orlando, Florida • Tampa, Florida

Conditions: Triple Negative Metastatic Breast Cancer, BRCA-mutated Solid Tumor
Interventions: BMN-673, Carboplatin, Paclitaxel; Drug
Lead sponsor: Pamela Munster; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Advanced Cancer, Solid Tumors
Interventions: Sodium Stibogluconate, Interferon Alpha-2b; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 2
States / cities: Albuquerque, New Mexico • Houston, Texas

Conditions: Cancer
Interventions: acupuncture therapy, management of therapy complications, pain therapy; Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

BMS-247550 in Treating Patients With Advanced Cancers

Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors

CpG 7909/Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1 Protein for NY-ESO-1-expressing Tumors

Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Adult Participants With Advanced PD-L1 Positive Malignancies

Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer

Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

Radiofrequency Ablation and External-Beam Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer

Vaccine Response With NT-I7

Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer

A Study of the Absorption, Metabolism, and Excretion of [14C]-AMG 510 Following a Single Oral Dose in Healthy Male Subjects

Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors

Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults

Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment

Phase I Protocol for the Evaluation of the Safety and Immunogenicity of Vaccination With Synthetic HIV Envelope Peptides in Patients With Early Human Immunodeficiency Virus Infection

A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors

The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects

XY-Zone Program Evaluation: A School-Based Dropout Prevention Program for At-Risk Youth

A Study to Test the Safety of the Study Drug Fosmanogepix and How the Body Handles It in Adults With Severe Kidney Failure on Dialysis

Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer

Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies

Acupuncture in Treating Mucositis-Related Pain Caused by Chemotherapy in Patients Undergoing Stem Cell Transplantation